ERBB3 and cancer: ERBB2 mutations were most prevalent in bladder (8.8%), small bowel (7.4%), urinary tract (5.9%), cervical (4.8%), and salivary gland (3.9%) cancers, whereas ERBB3 mutations were most prevalent in small bowel (5.3%), bladder (5.2%), urinary tract (4.0%), GEC (2.3%), and uterine (2.1%) cancers (Fig. 1A and B).